Welcome to our dedicated page for IGC Pharma SEC filings (Ticker: IGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IGC Pharma, Inc. filings document a clinical-stage biotechnology issuer with common stock listed on NYSE American under the symbol IGC. The company's regulatory disclosures cover material-event reports, operating and financial results, clinical and regulatory updates tied to Alzheimer's disease programs, and capital-structure matters including promissory note financing and authorized share changes.
Form 8-K disclosures also record amendments to governing documents, the fiscal year-end change to December 31, shareholder voting results, board election and auditor ratification matters, and equity incentive share approvals. These filings frame the company's governance, financing arrangements, reporting calendar and development-stage disclosure profile.
IGC Pharma, Inc. is furnishing an updated investor presentation that focuses on IGC-AD1, an investigational oral liquid therapy in development for agitation in Alzheimer’s disease and related neuropsychiatric symptoms. The materials describe the multicenter CALMA Phase 2 trial for agitation in Alzheimer’s dementia, which has a target enrollment of 146 participants, with more than 80% reported as having completed dosing, and identify upcoming catalysts such as completion of enrollment and a topline readout.
The presentation highlights Phase 1 results in which IGC-AD1 was associated with improvements in Neuropsychiatric Symptoms measured by the NPI-12 scale, including a Cohort 1 total average score change from 31.5 at baseline to 14.8 at Day 15, a 53.02% reduction (p=0.005). It also provides blinded pooled CALMA Phase 2 CMAI agitation data that cannot establish treatment effect or efficacy, market context showing widespread agitation in Alzheimer’s, and a portfolio of multiple patent families. The company emphasizes that IGC-AD1 remains investigational and unapproved, that interim and blinded data are preliminary and may not predict final results, and that all valuation and market scenarios are illustrative and hypothetical.
IGC Pharma, Inc. entered into stock purchase agreements with its CEO Ram Mukunda and PFO Claudia Grimaldi, converting company payables into equity. The executives bought common stock at $0.27 per share, paid for by cancelling amounts the company owed them, including prior personal cash advances.
The company issued 2,226,475 shares to Mr. Mukunda in exchange for $601,148 of obligations and 2,048,378 shares to Ms. Grimaldi for $553,062. In total, $1,154,210 of outstanding obligations were eliminated with a corresponding increase in stockholders’ equity, and no cash left the company. The transactions were approved by independent directors and relied on a private-offering exemption under securities laws, with the new shares issued as restricted securities.
IGC Pharma CEO Mukunda Ram acquired 2,226,475 shares of common stock in a private placement by cancelling $601,148 of debt the company owed him. The shares were issued at $0.27 each as restricted securities under Rule 144, in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. The deal was approved in advance by disinterested directors and the Audit Committee for Rule 16b-3 purposes, and Ram now directly holds 6,875,563 shares of IGC Pharma common stock.
IGC Pharma director and principal financial officer Claudia Grimaldi acquired 2,048,378 shares of common stock in a debt-for-equity swap. The shares were obtained at $0.27 per share in a private placement in exchange for cancellation of $553,062 of indebtedness owed to her by the company.
Following this transaction, she directly holds 3,421,092 common shares. The new shares are restricted securities under Rule 144 and were issued under a Section 4(a)(2) private placement exemption, with approval by disinterested directors and the Audit Committee for Rule 16b-3 purposes.
IGC Pharma, Inc. entered into an amendment with O-Bank Co., Ltd. on June 5, 2026, to extend its existing Master Loan and Security Agreement and General Banking Facility Letter. The banking facility continues to provide a maximum aggregate limit of $12,000,000 for the company.
Key terms remain substantially unchanged from the June 24, 2025 facility letter, except the facility fee has increased from $48,000 to $60,000. The agreement is characterized as a material definitive agreement and also creates a direct financial obligation for IGC under Item 2.03.
IGC Pharma, Inc. reports results for the quarter ended March 31, 2026, as it advances its Alzheimer’s pipeline and AI platforms. Revenue was $317 thousand, slightly below $330 thousand a year earlier, and still comes mainly from life sciences wellness and white‑label products rather than drug sales. The company posted a net loss of $2.4 million, double the $1.2 million loss in the prior-year quarter, driven by higher R&D spending on the Phase 2 CALMA trial of IGC-AD1 and increased stock-based compensation. Cash and cash equivalents fell to $207 thousand, with a working capital deficit of $1.7 million, partly mitigated by $710 thousand of new equity and debt financing, a $12 million credit facility, and cost actions including the sale of a loss-making facility. Management expects continued operating losses while focusing on completing the CALMA trial, developing the MINT-AD AI platform, and progressing additional Alzheimer’s candidates.
IGC Pharma entered into two securities purchase agreements, issuing promissory notes to FirstFire Global Opportunities Fund and Vanquish Funding Group to raise cash for general working capital. The FirstFire note has a principal of $346,910 (including original issue discount) and matures on April 10, 2027, while the VFG note has a principal of $238,050 and matures on March 30, 2027.
Both notes carry a 12% interest rate and may be prepaid in full with notice. If an Event of Default occurs and continues, each holder may convert amounts outstanding into common stock at a price equal to 75% of the lowest trading price over the prior ten trading days, subject to a 4.99% beneficial ownership limit and an overall 19.99% Conversion Cap unless shareholders approve more under NYSE American rules.
IGC Pharma director Richard K. Prins exercised restricted stock units into common shares of the company. On April 1, 2026, he converted 170,000 restricted stock units into 170,000 shares of common stock at an exercise price of $0.00 per share. Following these transactions, he directly holds 1,541,251 shares of IGC Pharma common stock. The units were granted in June 2023 and March 2024 and vest in equal installments over three years, with each unit representing one share of common stock.
IGC Pharma, Inc. CEO Mukunda Ram reported multiple equity award exercises on April 1, 2026. He exercised restricted stock units and stock options to acquire a total of 706,409 shares of common stock, including shares held indirectly through his spouse, with no open-market sales.
Following these transactions, Ram directly holds 4,649,088 shares of IGC Pharma common stock, while his spouse holds an additional 910,751 shares reported as indirect ownership. The filing reflects routine compensation-related vesting and option exercises rather than discretionary buying or selling.
IGC Pharma director James P. Moran reported routine equity compensation activity involving restricted stock units (RSUs). On April 1, 2026, he exercised 80,000 RSUs and 50,000 RSUs, each RSU converting into one share of IGC common stock at a $0.00 exercise price. These RSUs stem from grants made on June 20, 2023 and March 13, 2024 that vest in equal annual installments over three years. Following the conversions, Moran directly owns 1,235,735 shares of IGC Pharma common stock, with no open‑market sales disclosed in this filing.